hydroquinone has been researched along with Facial Dermatoses in 31 studies
Facial Dermatoses: Skin diseases involving the FACE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 7.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| " Purpose: Though hydroquinone (HQ) remains the gold standard for treatment of hyperpigmentation, concerns about its safety have prompted the development of HQ-free topical skin lightening systems." | 5.24 | A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation. ( Bolton, J; Goldman, MP; Jones, IT; Larsen, L; Vanaman Wilson, MJ; Wu, DC, 2017) |
| "There was no significant difference in the incidence of post-CO2 laser resurfacing hyperpigmentation between subjects who received pretreatment with either topical glycolic acid cream or combination tretinoin/hydroquinone creams and those who received no pretreatment regimen." | 5.09 | Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. ( Alster, TS; West, TB, 1999) |
| "In this prospective pilot study, we evaluated the efficacy and safety for a novel combination therapy based on low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis." | 3.85 | A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis. ( Choi, SC; Jung, JY; Kwon, HH; Kwon, IH; Ohn, J; Park, GH; Park, HY; Suh, DH, 2017) |
| "We present a case of exogenous ochronosis in a 53-year-old woman with skin type IV, who used a topical hydroquinone preparation of an unknown concentration for several years." | 3.80 | Exogenous ochronosis. ( Hale, CS; Leger, M; Meehan, SA; Nagler, A, 2014) |
| "Exogenous ochronosis (EO), a disfiguring cutaneous complication of topical hydroquinone use, is difficult to treat." | 3.79 | Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser. ( Tan, SK, 2013) |
| "We describe a 63-year-old Hispanic woman who developed exogenous ochronosis lesions on her face after using topical bleaching creams containing hydroquinone, 2% to 3%, and oxybenzone, 2%, for several years." | 3.76 | Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis. ( Gil, I; Herrero-González, JE; Lloreta, J; Martínez-Escala, E; Puig, S; Pujol, RM; Segura, S; Vélez, M, 2010) |
| "A 55-year-old woman with melasma develops biopsy-proved exogenous ochronosis in the setting of prolonged topical hydroquinone use." | 3.74 | Exogenous ochronosis. ( Brown, L; Meehan, S; Merola, JF; Walters, RF, 2008) |
| " Safety was assessed through the reporting of adverse events." | 2.73 | A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. ( Chan, R; Chang, SE; Kerrouche, N; Lee, ES; Lee, MH; Legarda-Montinola, F; Leow, YH; Park, KC; Shek, S; Tay, YK; Thomas, G; Tsai, RY; Tsai, TH; Verallo-Rowell, V, 2008) |
| "Melasma is a common hyperpigmentation disorder that is frequently recalcitrant to treatment." | 2.72 | Community-based trial of a triple-combination agent for the treatment of facial melasma. ( Grimes, P; Kelly, AP; Torok, H; Willis, I, 2006) |
| " only 3 patients (1%) withdrew from the study due to treatment-related adverse events (AEs)." | 2.71 | Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. ( Jones, T; Rich, P; Smith, S; Torok, HM; Tschen, E, 2005) |
| "Melasma is difficult to clear." | 2.69 | Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. ( Lim, JT, 1999) |
| "Acne was the most frequent motive for consulting (24%), followed by the paradoxical peri-orbital hyperpigmentation (21." | 1.33 | [Reasons for consulting related to skin-bleaching products used by 104 women in Brazzaville]. ( Gathse, A; Ibara, JR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pirrone, J | 1 |
| Broyer, J | 1 |
| Otte, N | 1 |
| Reich, K | 1 |
| Boer-Auer, A | 1 |
| Vanaman Wilson, MJ | 1 |
| Jones, IT | 1 |
| Bolton, J | 1 |
| Larsen, L | 1 |
| Wu, DC | 1 |
| Goldman, MP | 1 |
| Sánchez-Martínez, EM | 1 |
| García-Briz, MI | 1 |
| Moneva-Léniz, LM | 1 |
| Gegúndez-Hernández, H | 1 |
| Pose-Lapausa, P | 1 |
| Mateu-Puchades, A | 1 |
| Tan, SK | 1 |
| Kindem, S | 1 |
| Serra-Guillén, C | 1 |
| Guillén, C | 1 |
| Nagler, A | 1 |
| Hale, CS | 1 |
| Meehan, SA | 1 |
| Leger, M | 1 |
| Cinotti, E | 1 |
| Labeille, B | 1 |
| Douchet, C | 1 |
| Cambazard, F | 1 |
| Perrot, JL | 1 |
| Kwon, HH | 1 |
| Ohn, J | 1 |
| Suh, DH | 1 |
| Park, HY | 1 |
| Choi, SC | 1 |
| Jung, JY | 1 |
| Kwon, IH | 1 |
| Park, GH | 1 |
| Sarkar, R | 1 |
| Parmar, NV | 1 |
| Kapoor, S | 1 |
| Córdova, ME | 1 |
| Pérez-Rojas, DO | 1 |
| López-Marquet, AD | 1 |
| Arenas, R | 1 |
| Chan, R | 1 |
| Park, KC | 1 |
| Lee, MH | 1 |
| Lee, ES | 1 |
| Chang, SE | 1 |
| Leow, YH | 1 |
| Tay, YK | 1 |
| Legarda-Montinola, F | 1 |
| Tsai, RY | 1 |
| Tsai, TH | 1 |
| Shek, S | 1 |
| Kerrouche, N | 1 |
| Thomas, G | 1 |
| Verallo-Rowell, V | 1 |
| Merola, JF | 1 |
| Meehan, S | 1 |
| Walters, RF | 1 |
| Brown, L | 1 |
| Gil, I | 1 |
| Segura, S | 1 |
| Martínez-Escala, E | 1 |
| Lloreta, J | 1 |
| Puig, S | 1 |
| Vélez, M | 1 |
| Pujol, RM | 1 |
| Herrero-González, JE | 1 |
| Yoon, TY | 1 |
| Lee, GC | 1 |
| Kim, YG | 1 |
| Kim, MK | 1 |
| Kim, CY | 1 |
| Grimes, PE | 1 |
| Torok, HM | 1 |
| Jones, T | 1 |
| Rich, P | 1 |
| Smith, S | 1 |
| Tschen, E | 1 |
| Gathse, A | 1 |
| Ibara, JR | 1 |
| Grimes, P | 1 |
| Kelly, AP | 1 |
| Torok, H | 1 |
| Willis, I | 1 |
| Hexsel, D | 1 |
| Arellano, I | 1 |
| Rendon, M | 1 |
| Ferreira Cestari, T | 1 |
| Hassun, K | 1 |
| Sittart, A | 1 |
| de Lourdes Viegas, M | 1 |
| Lupo, MP | 1 |
| Jacyk, WK | 1 |
| Rubin, MG | 1 |
| Camarasa, JG | 1 |
| Serra-Baldrich, E | 1 |
| Snider, RL | 1 |
| Thiers, BH | 1 |
| Apfelberg, DB | 1 |
| West, TB | 1 |
| Alster, TS | 1 |
| Lim, JT | 1 |
| Ozluer, SM | 1 |
| Muir, J | 1 |
| Barrientos, N | 1 |
| Ortiz-Frutos, J | 1 |
| Gómez, E | 1 |
| Iglesias, L | 1 |
| Melli, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.[NCT00975312] | Phase 2 | 22 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for hydroquinone and Facial Dermatoses
| Article | Year |
|---|---|
A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Topics: Administration, Cutaneous; Adult; Aged; Dermatologic Agents; Facial Dermatoses; Female; Humans; Hydr | 2017 |
Treatment of Postinflammatory Hyperpigmentation With a Combination of Glycolic Acid Peels and a Topical Regimen in Dark-Skinned Patients: A Comparative Study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Chemexfoliation; Drug Combinations; Faci | 2017 |
A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Topics: Administration, Cutaneous; Adult; Analysis of Variance; Asian People; Double-Blind Method; Drug Comb | 2008 |
A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Topics: Administration, Topical; Adult; Dermatologic Agents; Drug Administration Schedule; Drug Combinations | 2004 |
Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.
Topics: Antioxidants; Drug Combinations; Facial Dermatoses; Female; Fluocinolone Acetonide; Glucocorticoids; | 2005 |
Community-based trial of a triple-combination agent for the treatment of facial melasma.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Dermato | 2006 |
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
Topics: Administration, Topical; Adult; Drug Combinations; Emollients; Facial Dermatoses; Female; Fluocinolo | 2007 |
Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing.
Topics: Administration, Cutaneous; Adult; Carbon Dioxide; Dermatologic Surgical Procedures; Facial Dermatose | 1999 |
Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid.
Topics: Adult; Aspergillus oryzae; Double-Blind Method; Drug Combinations; Facial Dermatoses; Female; Gels; | 1999 |
22 other studies available for hydroquinone and Facial Dermatoses
| Article | Year |
|---|---|
Extensive hyperpigmentation of the face in a Filipina.
Topics: Administration, Topical; Diagnosis, Differential; Facial Dermatoses; Female; Hispanic or Latino; Hum | 2017 |
Exogenous ochronosis: the failure of depigmenting creams.
Topics: Antioxidants; Back; Facial Dermatoses; Female; Humans; Hydroquinones; Hyperpigmentation; Middle Aged | 2019 |
Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser.
Topics: Adult; Aged; Asian People; Facial Dermatoses; Female; Humans; Hydroquinones; Hyperpigmentation; Lase | 2013 |
Patchy facial hyperpigmentation.
Topics: Facial Dermatoses; Female; Humans; Hydroquinones; Middle Aged; Ochronosis; Skin Lightening Preparati | 2015 |
Exogenous ochronosis.
Topics: Antioxidants; Facial Dermatoses; Female; Humans; Hydroquinones; Middle Aged; Ochronosis | 2014 |
[Role of dermoscopy and reflectance confocal microscopy as an aid in the diagnosis of exogenous ochronosis].
Topics: Adult; Biopsy; Dermoscopy; Facial Dermatoses; Female; Humans; Hydroquinones; Macrophages; Melanins; | 2016 |
A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Combined Modality Therapy; Erythema; Facial | 2017 |
Exogenous Ochronosis in Facial Melasma.
Topics: Dermoscopy; Facial Dermatoses; Female; Homogentisate 1,2-Dioxygenase; Homogentisic Acid; Humans; Hyd | 2017 |
Exogenous ochronosis.
Topics: Dermatologic Agents; Diagnosis, Differential; Facial Dermatoses; Female; Humans; Hydroquinones; Mela | 2008 |
Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis.
Topics: Benzophenones; Biopsy, Needle; Cosmetics; Dermoscopy; Facial Dermatoses; Female; Follow-Up Studies; | 2010 |
A case of idiopathic eruptive macular pigmentation.
Topics: Adult; Diagnosis, Differential; Dicarboxylic Acids; Facial Dermatoses; Female; Humans; Hydroquinones | 2004 |
[Reasons for consulting related to skin-bleaching products used by 104 women in Brazzaville].
Topics: Acne Vulgaris; Adolescent; Adrenal Cortex Hormones; Adult; Congo; Cosmetics; Dermatologic Agents; De | 2005 |
Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation.
Topics: Administration, Topical; Drug Therapy, Combination; Facial Dermatoses; Fluocinolone Acetonide; Gluco | 2006 |
Dermatosis papulosis nigra: treatment options.
Topics: Black People; Facial Dermatoses; Female; Humans; Hydroquinones; Laser Therapy; Postoperative Care; R | 2007 |
Annular granulomatous lesions in exogenous ochronosis are manifestation of sarcoidosis.
Topics: Adult; Aged; Collagen; Diagnosis, Differential; Elastic Tissue; Eosinophils; Facial Dermatoses; Fema | 1995 |
Chemical peeling as adjuvant therapy for facial neurotic excoriations.
Topics: Chemexfoliation; Facial Dermatoses; Glycolates; Humans; Hydroquinones; Hydroxy Acids; Neurotic Disor | 1995 |
Exogenous ochronosis with allergic contact dermatitis from hydroquinone.
Topics: Dermatitis, Allergic Contact; Drug Eruptions; Facial Dermatoses; Female; Humans; Hydroquinones; Midd | 1994 |
Exogenous ochronosis.
Topics: Administration, Cutaneous; Dermatologic Agents; Facial Dermatoses; Female; Humans; Hydroquinones; Mi | 1993 |
Ultrapulse carbon dioxide laser with CPG scanner for full-face resurfacing for rhytids, photoaging, and acne scars.
Topics: Acne Vulgaris; Acyclovir; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antiviral Agents | 1997 |
Nail staining from hydroquinone cream.
Topics: Administration, Topical; Adult; Coloring Agents; Facial Dermatoses; Follow-Up Studies; Humans; Hydro | 2000 |
Allergic contact dermatitis from a bleaching cream.
Topics: Allergens; Dermatitis, Allergic Contact; Diagnosis, Differential; Facial Dermatoses; Female; Humans; | 2001 |
[Clinical evaluation of the efficacy of a topical preparation containing 2% hydroquinone in chloasma].
Topics: Administration, Topical; Adult; Facial Dermatoses; Female; Humans; Hydroquinones; Melanosis; Middle | 1987 |